Wedbush Assumes Coverage on Anadys Pharmaceuticals (ANDS) at Outperform; High Risk / Potentially High Reward
Tweet
Share
E-mailGet Alerts ANDS Hot Sheet
Price: $3.70 --0%
Rating Summary:
0 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
0 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Wedbush assumes coverage on Anadys Pharmaceuticals (NASDAQ: ANDS) with a Outperform. PT lowered from $3 to $2.
Wedbush analyst says, "The company’s core asset, ANA598 (Setrobuvir) is a wellcharacterized drug candidate directed to the high-profile HCV market, and
one of few unpartnered assets nearly ready for Phase IIb DAA combination studies. However, as a non-nucleotide (non-nuke), ANA598 belongs to a somewhat less-favored class of drug candidates, and may have difficulty attracting partnership interest, in our view. That said, we believe ANDS presents a compelling argument why ANA598 may prove to be a particularly effective HCV drug."
For more ratings news on Anadys Pharmaceuticals click here and for the rating history of Anadys Pharmaceuticals click here.
Shares of Anadys Pharmaceuticals closed at $1.00 yesterday.
Wedbush analyst says, "The company’s core asset, ANA598 (Setrobuvir) is a wellcharacterized drug candidate directed to the high-profile HCV market, and
one of few unpartnered assets nearly ready for Phase IIb DAA combination studies. However, as a non-nucleotide (non-nuke), ANA598 belongs to a somewhat less-favored class of drug candidates, and may have difficulty attracting partnership interest, in our view. That said, we believe ANDS presents a compelling argument why ANA598 may prove to be a particularly effective HCV drug."
For more ratings news on Anadys Pharmaceuticals click here and for the rating history of Anadys Pharmaceuticals click here.
Shares of Anadys Pharmaceuticals closed at $1.00 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- Axis Capital Limited Assumes Jubilant Foodworks Ltd (JUBI:IN) at Reduce (3)
- Raymond James Starts SpyGlass Pharma (SGP) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
